Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

The St. Louis Business Journal's Innovation in Philanthropy Awards program, now in its sixth year, celebrates local ...

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive ...

after the company provided a “long-awaited” update for its Phase 3 study design and timeline of zorevunersen for the treatment of Dravet syndrome. While some investors appeared to be ...

This trial will investigate zorevunersen as a potential treatment for Dravet syndrome, a severe form of epilepsy in children. The study, slated to begin in mid-2025, will assess the efficacy of ...

The proposed study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg over 52-weeks compared to sham in children and adolescents ages 2 to <18 with Dravet syndrome.

It is formulated as a solution for oral route of administration. Epidiolex is indicated for the treatment of seizures associated with Lennox-gastaut syndrome or dravet syndrome in patients 2 years of ...